Altasciences Completes Clinical Portion of Alzamend Neuro’s Phase IIa Multiple Ascending Dose Clinical Trial for Treatment of Dementia Related to Alzheimer’s
Altasciences is proud to support Alzamend Neuro, Inc. (Alzamend) in advancing a novel treatment for dementia related to Alzheimer’s disease (Alzheimer’s). In addition to having conducted Alzamend’s Phase IIa multiple ascending dose (MAD) clinical trial in healthy subjects, Altasciences is continuing to provide clinical monitoring, project management, biostatistics, pharmacokinetics (PK), bioanalysis, and medical writing solutions as the product candidate is evaluated in Alzheimer’s patients.
The purpose of the MAD study conducted at Altasciences’ Montréal clinical pharmacology unit, was to evaluate the safety and tolerability of AL001 under multiple-dose, steady-state conditions; to determine the maximum tolerated dose in healthy young and elderly study participants; and to allow Alzamend to proceed to the next step: dosing in planned subsequent Phase IIa clinical trials involving Alzheimer’s, bipolar disorder, major depressive disorder (MDD), and post-traumatic stress disorder (PTSD) subjects.
“Our Phase I study was successfully conducted with Altasciences and we are excited to continue this partnership with our Phase IIa MAD study,” said Stephan Jackman, Chief Executive Officer of Alzamend. “We strongly believe that AL001’s patented ionic cocrystal technology may constitute a means of treating over 40 million Americans suffering from Alzheimer’s, bipolar disorder, MDD, and PTSD. We look forward to reporting topline data in June 2023 and further advancing clinical development of this promising potential therapeutic.”
The clinical and PK data generated during the clinical portion of the MAD study are undergoing evaluation by Altasciences to characterize the safety and drug exposure in healthy subjects, as well as Alzheimer’s patients.
“Altasciences’ mission is to help sponsors bring promising novel treatments, like AL001, to the people who need them, faster,” says Marie-Hélène Raigneau, Co-chief Operating Officer. “ Our team takes immense pride in the role we play to help improve lives through drug development, and is delighted to continue our valued partnership with Alzamend.”
Altasciences has decades of experience with early phase drug development, supporting sponsors with an end-to-end solution, from preclinical studies to clinical proof of concept, and beyond.
Altasciences is an integrated drug development solution company offering pharmaceutical and biotechnology companies a proven, flexible approach to preclinical and clinical pharmacology studies, including formulation, manufacturing, and analytical services. For over 25 years, Altasciences has been partnering with sponsors to help support educated, faster, and more complete early drug development decisions. Altasciences’ integrated, full-service solutions include preclinical safety testing, clinical pharmacology and proof of concept, bioanalysis, program management, medical writing, biostatistics, clinical monitoring, and data management, all customizable to specific sponsor requirements. Altasciences helps sponsors get better drugs to the people who need them, faster. To learn more about Altasciences, visit altasciences.com.
About Alzamend Neuro
Alzamend is a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s, bipolar disorder, major depressive disorder and post-traumatic stress disorder. Their mission is to rapidly develop and market safe and effective treatments. Their current pipeline consists of two novel therapeutic drug candidates, AL001, a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate; and ALZN002, a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient’s immunological system to combat Alzheimer’s. Both of our product candidates are licensed from the University of South Florida Research Foundation, Inc. pursuant to royalty-bearing exclusive worldwide licenses. To learn more about Alzamend, visit alzamend.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230418005095/en/
+1 514 601-9763
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
UAE’s In-Country Value Projects Driving Billions to Local Firms1.6.2023 19:40:00 EEST | Press release
More than $27.23 billion has been redirected to the local economy since the UAE Ministry of Industry and Advanced Technology (MoIAT) and ADNOC launched major in-country value programs to support domestic industries. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230601005886/en/ Sideline of Make It In The Emirates Forum (Photo: AETOSWire) Speaking at the Make in the Emirates Forum today, His Excellency Abdulla Al Shamsi, Assistant Undersecretary of MoIAT, said more than $14.43 billion of investment was redirected to the local economy last year alone, an increase of 25 percent year-on-year. “The National In-Country Value Program is a nationwide program that speaks one language across many different sectors,” HE said. “It’s one methodology and this is something we’re very proud of because it benefits the private sector and when the private sector sees this it helps them prepare, invest, and spend.” The forum heard how the Nati
Carbios and Indorama Ventures Reaffirm Partnership to Build First-of-a-kind PET Biorecycling Plant in France1.6.2023 19:30:00 EEST | Press release
Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230601005872/en/ Carbios and Indorama Ventures reaffirm partnership to build first-of-a-kind PET biorecycling plant in France Carbios (Euronext Growth Paris: ALCRB), a biotech company developing and industrializing biological solutions to reinvent the life cycle of plastic and textiles, and Indorama Ventures Public Company Limited (IVL) (Bloomberg ticker IVL.TB), a global sustainable chemical producer, announce today the signing of a non-binding Memorandum of Understanding (MOU) to form a Joint Venture for the construction of the world’s first PET biorecycling plant in France1. Based on and subject to the comprehensive terms set out in the MOU, Indorama Ventures plans to mobilize about €110 million for the Joint Venture in equity and non-convertible loan financing2, pending final engineering documentation and final economic feasibility studies. Both parties have
PPG opens Color Creation Lab with Chery Automobile in China1.6.2023 16:01:00 EEST | Press release
PPG (NYSE:PPG) today announced the opening of a Color Creation Lab in collaboration with automaker Chery Automobile Co., Ltd. At the facility, located in Wuhu, China, PPG color stylists and Chery designers will create new colors tailored to specific vehicle designs, from initial color recommendations to final materials for application in Chery’s manufacturing plants. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230601005119/en/ Representatives from PPG and Chery Automobile celebrate the opening of a Color Creation Lab in Wuhu, China. (Photo: PPG) “As the leading single-source coatings supplier for automotive manufacturing, PPG is excited to partner with Chery, a company that prioritizes technological innovation and sustainable production,” said Thomas Li, PPG vice president Asia Pacific, Automotive Coatings. “We will leverage our global color leadership to predict future trends, while advancing paint technology for the nex
HEINZ® Unveils First Global Creative Brand Platform in Over 150 Years1.6.2023 16:00:00 EEST | Press release
Today, HEINZ announces “It Has to be HEINZ,” a new global platform marking the first time in its 150-year history where the brand is unified under one creative strategy. The campaign pays homage to the brand by celebrating the irrational love people have for HEINZ – from real fans’ personal love affairs with the brand, to the love and care its products are made with. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230601005186/en/ HEINZ announces its first new global platform in its 150-year history “It Has to be HEINZ,” inspired by real-life stories of fans’ undeniable love of HEINZ (Graphic: Business Wire) Anchored by Kraft HEINZ’s largest media investment to date, the global creative platform demonstrates the unmatched love generations of people all over the world have for HEINZ – from Ketchup to Beanz and everything in-between(z). The fan stories featured in the creative – such as HEINZ tattoos, carrying condiment packets
PPG opens $30-million battery pack application center in China1.6.2023 16:00:00 EEST | Press release
PPG (NYSE: PPG) today announced that it has inaugurated a battery pack application center (BPAC) in Tianjin, China. The $30-million facility features a full range of capabilities to test the application of PPG coatings technologies, materials and systems for electric vehicle (EV) battery packs, allowing customers to accelerate the development of new EV technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230601005106/en/ PPG has inaugurated a $30-million facility in Tianjin, China to test coatings technologies, materials and systems for electric vehicle battery packs. (Photo: Business Wire) “The new application center is an important milestone in our effort to support our customers in China in the EV battery market,” said Vincent Robin, PPG global vice president, Automotive Coatings. “The new facility will be an important way for customers to validate our customizable coatings solutions that help them reduce applicat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom